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Telomeres Notchare thought to be stem cells with osteogenic potential and therefore responsible
for the repair and maintenance of the skeleton. Age related bone loss is one of the most prevalent diseases in
the elder population. It is controversial whether MSC undergo a process of aging in vivo, leading to decreased
ability to form and maintain bone homeostasis with age. In this review we summarize evidence of MSC
involvement in age related bone loss and suggest new emerging targets for intervention.
Crown Copyright © 2009 Published by Elsevier B.V. All rights reserved.1. IntroductionHuman aging is associated with bone loss leading to bone fragility
and increased risk for fractures, a disease known as osteoporosis.
Osteoporosis is one of the most prevalent and serious diseases
affecting the elderly population and constitutes a major public health
problem. The cellular and molecular causes of age-related bone loss
are currently intensive topics of investigation with the aim of
identifying new approaches to prevent and treat osteoporotic bone
loss. The aim of this review is to summarize the recent literature that
relates senescence of stromal (also known as mesenchymal stem cells
and abbreviated MSC) to aged-related decrease in bone formation.
2. The concept of bone remodelling in relation to MSC
Bone as a tissue, is composed of bone matrix and bone cells. Two
main types of mature bone cells have been identiﬁed: osteoblasts
(bone forming cells) and osteoclasts (bone resorbing cells) [1]. The
main function of those cells is to mediate a bone replacement
mechanism called “bone remodelling” aiming at maintenance of the
integrity of the skeleton by removing old bone of highmineral densitycontacted at Room DU19,
ntistry and Health, University
+44 114 271179; fax: +44 114
Center, Winslowsparken 25,
uono), mkasem@health.sdu.dk
09 Published by Elsevier B.V. All riand high prevalence of fatigue micro-fractures and replacing it with
young bone of low mineral density and better mechanical properties
[1,2]. Bone remodelling comprises a speciﬁc sequence of cellular
events. It starts with recruitment of osteoclast precursors, their fusion
to form mature osteoclasts followed by their migration to bone
surfaces. The osteoclasts remove an amount of bone and create a
resorption lacuna. Bone resorption is followed temporally in the same
anatomical location by bone formation. Key to the initiation of the
process of bone formation is the recruitment of osteoblasts from stem
cells and precursor cells in the bonemarrow and theirmigration to the
bottom of the resorption lacuna. Osteoblasts deposit matrix that
mineralizes and forms lamellar bone. Usually the amount of bone
removed by the osteoclasts is equal to the amount of bone formed by
the osteoblasts and a stable bone mass is maintained. However, this is
not the case during aging. Increased bone resorption and/or decreased
bone formation can lead to bone loss. Based on a number of
histomorphometric studies performed on iliac crest biopsies, a
decrease in bone formation seems to be the principal pathophysiolo-
gical mechanism responsible for age-related decreased bone mass [2].
2.1. Mesenchymal stem cells and their contribution to bone formation
Bone formation is dependent on the number and the activity of
osteoblasts recruited at bone formation sites during bone remodelling.
It is assumed that osteoblasts are differentiated from osteoprogenitor
and stem cells present in the bonemarrow. Based on the pioneer work
of Friedenstein and co-workers [3], it has been recognised that the
non-hematopoietic compartment of bone marrow (known as boneghts reserved.
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osteogenic differentiation potential. In vivo transplantation of MSC in
syngeneic or immunodeﬁcient mice in ectopic sites resulted in the
formation of a mixture of tissues including bone, cartilage and
hematopoietic-supporting stroma [3,4]. However, the identity of these
cells, andwhether they hold true properties of stem cells is still matter
of debate (see below).
3. Biological characteristics of MSC
3.1. Are MSC stem cells?
Stem cells are deﬁned by their ability to reconstitute in vivo the
tissue of origin giving rise to all the differentiated mature cell types
present in that tissue and contributing to its long term maintenance
and repair. Stem cells differ from progenitor cells (also known as
transient amplifying cells). Progenitor cells exhibit extended prolif-
erative capacity and multipotent differentiation ability in vitro, but
have very little ability to contribute to long term tissue regeneration in
vivo. In contrast, to demonstrate “stemness” properties, cells have to
show the ability to regenerate the tissue of origin following
transplantation and possibly in serial transplantation studies. There
is very little evidence for long term skeletal regeneration capacity of
MSC in vivo. Transplantation of MSC by intravenous (iv) infusion has
shown disappointing results with low or no engraftment of the cells to
bone and bone marrow [5–8]. Inefﬁcient migration has been thought
as the cause of lack of engraftment [6,9]. However, intra-femoral
injection of a subset of murine marrow stromal cells showed limited
engraftment at the site of injection 4–6 weeks post-transplantation
with fewcells expressingosteoblasticmarkers [10], suggesting that the
quality of the cells injectedmay be themain cause of low engraftment.
More encouraging are the studies testing the preservation of
long term self-renewal by implantation of MSC in heterotopic sites
[4,11]. In a recent study by Sacchetti et al. [12], implantation of a
subpopulation of MSC, which are CD45low/CD146bright, regenerated
bone and stroma-supporting hematopoiesis in ectopic bone forma-
tion assay. Most importantly highly clonogenic CFU-F were re-
isolated from the implants, suggesting that some of the implanted
MSC underwent self-renewal in vivo. In the study by Quarto et al.
MSC isolated by plastic adherence and transduced with an
erythropoietin cDNA, were transplanted (along with hydroxyapatite
particles) under the skin of nude mice. The cells were able to form
bone and bone marrow stroma and the animals maintained
increased hematocrit levels for 12–14 weeks [13]. More interestingly
MSC were re-isolated from the implants and used in secondary
transplantation showing sustained increased hematocrit levels
similar to those obtained in primary transplantation. These studies
provide a proof of principle that a stem cell with osteogenic
potential exists among MSC.Table 1
Markers used to perspectively isolate MSC from bone marrow
Marker Cross reaction % cells gen
CFU-F
Stro-1 [23,43,74] Erythroblasts,
B cells subset
9
Stro-1/VCAM [43] B cells 50
CD105 [75] Endothelial cells, pre B leukemic cells 0.006
CD271 (LNGFR) [76,77] Neural cells 0.16–1.9
CD45low D7 Fib/CD271 [78] D7Fib-skin ﬁbroblasts 15
SSEA4 [79] Embryonic (carcinoma) stem cells, germ cells N/D
GD2 [80] Neural cells N/D
CD45-CD146+ [81] CD146-T cells, melanoma, endothelial cells 2.6
N/D, not done.3.2. Identiﬁcation of MSC
The paucity of studies demonstrating stem cell properties of MSC
in vivo highlights the difﬁculties in the isolation and identiﬁcation of
the true MSC with self-renewing and multipotential differentiation
abilities. The absence of suitable markers to establish a hierarchical
relationship between stem and progenitor cells has left scientists with
a variety of protocols for the isolation of MSC, which vary from
laboratory to laboratory and rely mostly on physical–chemical
conditions of the in vitro culture. The most popular method for
isolating MSC from bone marrow is through plastic adherence [14,15].
The resulting MSC cultures are heterogeneous and contain a mix of
progenitors at different stages of commitment [15,16].
In vitro, MSC are identiﬁed retrospectively by their clonogenic
growth capacity (known as colony forming unit-ﬁbroblast CFU-F) and
their ability to differentiate into a broad spectrum of fully differ-
entiated connective tissues, including cartilage, bone, adipose tissue
and myelosupportive stroma in vitro [17]. However, remarkable
differences have been observed among the different CFU-Fs in terms
of cell morphology, rate of replication, expression of markers for
osteoblastic, chondroblastic, adipogenic phenotypes and the number
of differentiated progeny they can give rise to, with some CFU-F
capable of multipotent differentiation, others only capable of forming
bone and yet others capable of giving origin to myelo-supportive
stroma [15,16,18–21].
Unfortunately, there are no commonly accepted surface antigens,
which can be used to prospectively isolate MSC from bone marrow.
To-date the markers used are not speciﬁc to stemness characteristics
and are common to several mature cell types. MSC are recognised as
negative for CD45 (non-hematopoietic) CD34 (non-endothelial) and
positive for CD90, CD105 (SH2), CD73 (SH3), CD63, Stro-1 [22,23].
There have been several attempts to identify novel markers for
prospective isolation of MSC with stem cell properties (Table 1). Stro1
is among the ﬁrst and one of the most investigated marker. Stro-1
antibody identiﬁes a glycoprotein component on all the clonogenic
MSC [23]. However expression of Stro1 is not unique to MSC as it is
also expressed in erythroid precursors. Transplantation of Stro1+
cells in vivo did not show improved engraftment potential [7].
Moreover, there has been no evidence that Stro1+ cells have the
ability of in vivo self-renewal. It remains unclear whether Stro1
identiﬁes a population of cells, which is more primitive compared to
cells isolated by plastic adherence, and whether the more recently
isolated CD45low/CD146bright subpopulation of MSC [12] (see above)
performs better in serial transplantation. A turning point in the
establishment of a hierarchical relationship within the BMSC may be
represented by a recent study by Nishikawa's group [24]. The authors
examined the developmental origin of MSC, using murine ES cell as
model. A very early progenitor cell, the Sox1+ neuroepithelial cell was
identiﬁed as the primary cell of origin of MSC. Sox1+cellserating In vivo bone formation Re-isolation following
transplant
Telomerase
expression
Bone and
hematopoietic microenvironment
N/D Yes
Bone formation in 35/64 clones N/D Yes
Hematopoietic microenvironment
in 11/35 clones
N/D N/D N/D
N/D N/D N/D
N/D N/D N/D
Bone formation N/D N/D
N/D N/D N/D
Bone formation and hematopoietic
microenvironment in 2/4 clones
CD146+ cells
and CFU-F
N/D
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through the sequential acquisition of PDGFRα and PDGFRβ expres-
sion. It is unknown if any of the cells emerging from the Sox1+
PDGFRα and PDGFRβ populations were CD45low/CD146high or
whether any of these intermediate cell populations are present in
the post-natal human bone marrow.
4. Age-related changes in MSC
As mentioned above, stem cells are required for the continuous
supply of mature, functionally competent cells for normal tissue
turnover and regeneration. An age-related decrease in the number or
functional abilities of stem cells is thought to lead to tissue
deterioration. In the following we will review evidence that MSC
exhibit changes in their biological characteristics during aging that are
relevant for their bone forming abilities.
4.1. Age-related changes in size of the MSC pool
Considering the lack of appropriate markers and assays to identify
MSC it is not surprising that no agreement has been reached as to
whether MSC decrease in numbers with age and whether this has a
role in the decrease bone mass observed during aging. Several
investigators have utilized the in vitro clonogenic ability of CFU-F to
determine the number of MSC progenitors. Others have measured the
clonogenic ability of their osteoblastic-committed populations, the
CFU-O, which is alkaline phophatase positive and is obtained
following exposure of bone marrow cells to osteogenic supplements.
In rats a decrease in MSC number is reported but this is not consistent
in murine MSC (Table 2). The reason for this discrepancy may be
related to the experimental method utilized. In the murine studies,
the number of CFU-F has been corrected for the number of cells
present in the femur. In contrast in the rat and human studies, CFU-F
or CFU-O has been calculated as frequency of bone marrow mono-
nuclear cells. Moreover, age-related effects on MSC may be strain
dependent. This is well known from studies performed on hemato-
poietic stem cells (HSC), where the repopulation ability of HSC is
compromised with age in Balb/c but not in C57Bl/6 [25]. Similarly,
femoral bone density decreases with age in Balb/c but not in C57Bl/6Table 2
Summary of studies assessing age-related changes in mesenchymal stem cell numbers, Y= y
years, OA = Osteoarthritis
Specie Age Assay
Rats 6/12 mo (Y), 24 24 mo (O) CFU-O
Rats 4 mo (Y) 21 mo (O) CFU-F CFU-O
Mice 4/6 mo (Y), 24 mo (O) CFU-F CFU-O
Mice 3 to 15 mo CFU-F (N50 cells)
Mice 3 to 15 mo CFU-F (N50 cells)
Rats 5–6 weeks (Y), 18 mo (O) Bone nodule in cultur
Proliferation rate
Human 4 to 88 y (49 females) CFU-O (N50 cells)
Human 13–88 y (57 donors) CFU-O (N8 cells)
Human Only females (26 donors) CFU-O (N8cells)
Human 3–36 y (5 F and 14 M) CFU-O (N50 cells)
41–70 y (11 F and 11 M)
BM from vertebrae
Human 17–87 y (28 donors, BM sternum) CFU-F (N128 cells)
Human 17–87 y (28 donors, BM sternum) CFU-F (b32 cells)
Human 14–48 y (16 donors) CFU-F
28–87 y (57 patients with OA) CFU-O
69–97 (26 patients with osteoporosis) (Size in mm2)
Human 1–18 y (Y) and 59–76 y (O) CFU-F (N50 cells)
Human 22–44 y (10 F and 13 M) Stro1+/CFU-F (N16 c
66–74 (15 F) Stro1+ CFU-O (16 cel
58–83 y (12 F with osteoporosis)
Human 5–55 y (33 donors) CFU-F (N50 cells)
CD45lowD7ﬁb+CD27[26] suggesting that Balb/c mice can be more sensitive to age related
changes. Unfortunately most of the studies to assess MSC numbers
have been carried out in C57Bl/6 strain. Interestingly, the only study
partly carried out using Balb/c showed a decrease in the number of
CFU-F and CFU-O [82].
Discrepancies exist also in the human studies that examined the
effect of age on the number of CFU-F or CFU-O [27–34]. It is plausible
that these inconsistencies in the results are due to differences in the
methods and source of bone marrow samples utilized. Some studies
used bone marrow obtained during surgical procedures for treatment
of osteoarthritis or other operations, which may not represent the
bone marrow of a healthy aging population. Also, bone marrow was
obtained from different sites (spine, proximal knee, iliac crest) and
with different techniques. Some authors used bone marrow aspirates
and other used “ﬂushing” technique to remove bone marrow cells
from the bone fragments obtained during orthopaedic procedures.
Methods of collection of bone marrow aspirates can inﬂuence widely
the number of MSC present depending on the extent of blood
contamination. Moreover, the site of harvest may determine the type
of MSC obtained. Sacchetti et al. [12] showed that the more primitive
CD45low/CD146high MSC is contained in the bone marrow obtained
from the iliac crest and not from cells from the periosteum or
trabecular bone. Another important factor, which can inﬂuence the
outcome of the studies, is the way a CFU-F or a CFU-O is deﬁned. Some
investigators deﬁned a CFU as a group of cells with more than 16 cells
whilst other more then 50 cells. It is of interest that only the studies
where colonies with more than 50 cells were counted showed a
decrease with age (Table 2) and it raises the question whether these
two colony types represent different cell populations with different
biology.
In an attempt to overcome some of these experimental limitations,
Stenderup et al. [33] examined the number of CFU-F and CFU-O
present in Stro-1+cells isolated from bone marrow mononuclear cells
in 38 normal healthy volunteers (23 young and 15 old individuals)
and 13 patients with osteoporosis. No age-related effects on the total
number of CFU-O, CFU-F or CFU colony size was observed [33]. In
contrast, the number of CD45low/D7ﬁb+/LNGF+ cells was reported to
decrease with age andwas positively correlated to the number of CFU-
F [34]. However, the difference between the two studies may beoung donor, O= older donors, F= Female, M=Male, N=Number, mo=months, y=
Outcome Reference
Decrease [29]
30% decrease CFU [28]
No difference in CFU
Decrease in CFU-F and CFU-O [82]
Increase [83]
No increase if corrected for increase in cellularity [84]
e Decrease bone nodule [85]
No change in proliferative rates
Decrease [86]
No difference [87]
Decrease [87]
Decrease up to 40 y [88]
Decrease up to 30 y [30]
No change [30]
No difference [31]
Decrease [32]
ells) No difference with age or osteoporosis [33]
ls)
Decrease [34]
1+
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in the number of MSC with age was observed in the studies when a
higher number of young donors were included, suggesting that most
of the observed decline in the number of CFU-F occurs in early
adulthood when changes in the skeletal dynamics from a modelling
mode characteristic of skeletal growth and consolidation to a
remodelling dynamics characteristic of the adult skeleton occurs.
This is true for the study by Stolzing et al. [34] where the major
difference in CFU-F numbers occur between the adolescent group (age
below 20) and adult group (age above 20). This may also explain why
experiments employing rats showed a decline in the CFU-F number as
they continue to grow throughout their lifespan. Changes later in life
may be very small if at all, possibly present only in certain pathological
conditions. Similar observations have been reported in HSC where the
highest proliferative demands are present in the ﬁrst year of life and
changes after that are very small and difﬁcult to detect unless in
condition of high proliferative stress such as following transplantation
(reviewed in [35]).
4.2. Age-related changes in proliferative capacity of MSC
Due to the very property of self-renewal, the proliferation ability of
stem cells is expected to be extensive or even indeﬁnite. The effect of
donor age on the maximal proliferative potential of plastic adherent
bone marrow-derived MSC has been examined by several investiga-
tors. An age-related decline in the maximal life span from 30–40
population doublings in younger donors to 20 PD in older donors was
observed [32,36] suggesting that MSC lose proliferative capacity in
vivo as well as in vitro. This is mirrored by telomere shortening and
increased number of MSC showing signs associated with senescence
such as a change inmorphology (from spindle shape to large ﬂat cells)
[32,34,36], expression of cell senescence markers e.g. β galactosidase,
tumor suppressor TP53 and cell cycle regulator protein p21 [34,36]
and an increase in the levels of oxidized and glycated protein and
lipofuscin, metabolites present in senescent cells [34].
Several studies have demonstrated a signiﬁcant decrease in the
mean telomere restriction fragment (mTRF) in MSC obtained from
younger donors between the primary passage and the end of the
culture, which signiﬁcantly correlated with the number of population
doublings [18,32,37,38]. Most importantly, when MSC were cultured
for an equal number of population doublings, the telomere length in
younger donors was signiﬁcantly longer compared to older donors
[32,36]. If one assumes that all MSC undergo telomere shortening at
similar rates in vitro, these data imply that the difference in telomere
length seen between younger and older donors is due to loss of mTRF
occurring in vivo and can be estimated to be about 17 bp/year [32].
Measurement of telomere length in uncultured MSC is now required
to exclude that culturing of MSC of young and old donors does not
introduce a bias and that the difference in telomere length seen is
truly a reﬂection of a loss occurring in vivo. However the fact that the
telomere length of MSC obtained from fetal blood, liver and bone
marrow was signiﬁcantly higher (pb0.01) compared to adult MSC
[39], shows the loss of telomere length with developmental age and is
well in agreement with these data.
Theoretically, long-term growth of MSC requires maintenance of
telomere length that is usually accomplished by the presence of
telomerase activity an enzyme which adds telomeric repeats at the
end of chromosomes. In HSC expression of telomerase has been
shown to delay the process of aging although it did not prevent it [40].
It is controversial whether MSC express telomerase to sufﬁcient levels
to act in a similar way. Most of the studies agree that telomerase is not
expressed by MSC in culture [41,42]. However, only one study
suggested that telomerase may be expressed in a sub-population of
MSC expressing STRO-1bright VCAM+marker before their exposure to
in vitro culture conditions [43]. It is possible that, similarly to HSC, a
very primitive subpopulation of MSC expresses telomerase in vivo.However, upon isolation in culture, MSC lose part of their stemness
and telomerase is switched off. In support of this a very recent study
demonstrated that culture expanded human MSC underwent com-
mitment towards osteoblast lineage and expressed high levels of
osteogenic regulatory gene Cbfa1, and alkaline phosphatase. Low
levels hTERT transcripts and telomerase activity were detected at the
start but repressed by increased Cbfa1 expression [44].
4.3. Age-related changes in differentiation potential of MSC
Several studies have examined the effects of donor age on the
differentiation potential of MSC. One caveat to these studies is that, in
contrast to HSC, where assessment occurs following in vivo trans-
plantation, in vitro culture and expansion of MSC is a prerequisite for
performing differentiation studies and in several of these studies the
degree of in vitro culture prior to differentiation studies has not been
controlled. Their differentiation potential to the osteogenic lineage has
been the most investigated in relation to aging. Stenderup et al. [33]
and Justesen et al. [45], cultured MSC from younger, older and
osteoporotic patients and found maintained osteoblast differentiation
potential at early passage in culture (low population doublings).
Similarly, Muraglia et al. tested the osteogenic, chondrogenic and
adipogenic differentiation capacity of MSC in donors of various ages
and found that the number of tripotent clones did not changewith age
in culture at early passage. However with time in culture the tripotent
clones lost their adipogenic potential [21].
Some studies have examined the effect of donor age on bone
forming capacity using in vivo bone formation assays. In this assayMSC
mixed with hydroxyapatite/tricalcium phosphate (HA/TCP) as a
carrier were implanted subcutaneously in syngeneic animals. Both
cells from younger and older donors were tested in both younger and
older recipient animals. MSC derived from aged rats exhibited
decreased bone formation capacity compared with MSC fromyounger
donors [46]. Stenderup et al. [11] employed similar methodology to
test the difference between MSC obtained at early passage (few
population doublings) from younger and older human donors. After
implantation in immune-deﬁcientmice, no differencewas found in the
amount of bone formed between the two age groups. On contrast,
Mendes et al. [47] demonstrated that when human MSC from 53
donors of various agewere seeded on calcium phosphate scaffolds and
implanted under the skin of nude mice, the ability of cultures for
forming bone declined with age with 67% of the culture able to form
bone at 41–50 years of age, 50% at 51–70 years of age and less that 46%
beyond 70 years of age. In conclusion, all these studies suggest that the
age-related changes of MSC capacity for osteoblast differentiation and
bone formationusing early passage (lowpopulationdoublings) ofMSC
are subtle and not consistent and may need sensitive assays for its
detection. However, the effect of donor age becomes clearer upon in
vitro expansion of the cells in culture due to an accelerated senescence
phenotype. These ﬁndings are of relevance to regenerative medicine
protocols where cells from elderly donor need to be used for therapy.
As mentioned above MSC can differentiate into osteoblasts and
other lineages including adipocytes. In vivo, several investigators have
demonstrated that with age there is a decrease in trabecular bone
volume (TBV), which is associated with increased bone marrow
adipocytic volume [48,49] and these changes are more pronounced in
osteoporotic patients. Furthermore, in a mouse model of accelerated
senescence (SAM-6 mouse) decreased bone formationwas associated
with enhanced adipogenesis in vivo and in vitro [50]. All these
ﬁndings led to the hypothesis that, MSC acquired a bias in the
differentiation ability in favour of the adipocyte lineage instead of the
osteoblastic lineage. Although initial studies on the in vitro differ-
entiation potential of MSC have reported that osteoblast differentia-
tion was inversely correlated to adipocyte cell differentiation [51,52],
these were superseded by numerous other studies where either no
difference was seen or MSC from older donors exhibited a decreased
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compared to younger donors. Thus, these studies suggest that
adipogenic differentiation from MSC can decline with age in vitro
but in vivo adipogenesis may be regulated independently andmay not
be necessarily related to impaired differentiation of MSC.
4.4. Age-related changes in bone microenvironment
Growth factors and cytokines are secreted in the bone micro-
environment, sequestrated in bonematrix and exert their main effects
locally as a controller of osteoblast activity during bone remodelling.
Several investigators measured the effect of donor age on the amount
of growth factors present in the bone matrix directly or indirectly
through bone inductive effects of demineralised bone matrix powder.
IGF-I and IGF-II are important regulators of osteoblastic cell prolifera-
tion and differentiation. Seck et al. [53] examined the relationship
between donor age, cortical bone content of IGF-I and IGF-II as well as
cortical bone remodelling in a large number of donors at different
ages. Bone samples were obtained from the proximal femur neck. The
authors found an age-related decrease in bonematrix concentration of
IGF-I in both men and women and of IGF-II in men only. However,
there was no signiﬁcant correlation between bone content of IGF-I,
IGF-II and any parameter of bone remodelling. From the same group,
production of transforming growth factor (TGF)-β did not change
with donor age [54].
Demineralised bone matrix (DBM) powder was implanted
subcutaneously in animals of different ages and the amount of
bone formed was quantitated using histomorphometric or biochem-
ical techniques. Irving et al. [55] found that bone induction capacity
of bone matrix is impaired in older animals. Bone powder obtained
from tibiae and femurs of 6-month-old rats was implanted
subcutaneously in young (6 weeks), adult (6 months), and old
(2 years) rat recipients. Bone was formed after 14 days in young rats,
after 15 days in adult rats and after 25 days in old rats. Similarly, the
bone induction of powder obtained from bones of 4-month-old rats
was dependent on recipient age with gradual decline in rats aged
1 month old to 16 months old [56]. Also, decreased in rates of bone
formation and amount of bone obtained after subcutaneous
implantation of DBM powder were observed in old rats (4 months
old) compared with young rats (4 weeks old) [57]. The decreased
bone formation found in rats was conﬁrmed in rabbits where 3, 6, 18,
and 28 months old rabbit recipients received intra-muscular
implantation of DBM powder from 6 month-old male rabbit donors
[58]. The amount of new bone formed was negatively correlated with
age of the recipient. Similar experiments were performed using
human DBM powder from younger (8 donors, 18–46 years) and older
donors (9 donor, 62–90 years) that were implanted subcutaneously
in mice [59]. The amount of bone formed by older donor DBM
powder was decreased compared with younger donors but the
difference was not statistically signiﬁcant. These studies suggest that
age-related changes in the bone microenvironment may play a role in
the decreased bone formation occurring with age. However, it is
unclear what cells are responsible for the change in growth factors
secretion. It is possible that stem cells as such change their cytokine
proﬁle secretion to modify the environment to suite their survival,
proliferation and differentiation needs. In an expression proﬁling
study Cairney et al. (in this issue) have shown increased secretion of
chemokines such as IL8 in HSC with age. MSC are known to secrete
cytokines such as IL6, or IL11 which have been shown to change with
age [60]. It is therefore possible that MSC exert an inﬂuence on the
changes in the microenvironment and in turn on the decreased bone
formation. Recently, we have employed serum as a surrogate for the
microenvironment “seen” by MSC. We compared the effect of sera
obtained from young and old donors on MSC proliferation and
differentiation [61]. We found that sera of elderly donors were
inhibitory to osteoblast and not adipocyte differentiation of MSC. Theputative factor(s) responsible for these effects remain to be
determined.
5. MSC aging and intervention to abolish age-related bone loss
Replacing or “rejuvenating” resident MSC populations by either
MSC transplantation or by activation of resident MSC by bioactive
molecules are potentially useful approaches to enhance the functional
capacity of MSC and represent a novel approach to increase in vivo
bone formation. During the recent years speciﬁc signaling pathways
have been identiﬁed that provide possible target for intervention.
Insight into these pathways has been obtained from studying human
diseases of progeria (or accelerated senescence) and through
combination of genetic studies and studying gene modiﬁed animal
models.
5.1. Telomerase and rejuvenation of MSC
As we described above, cultured MSC lack telomerase activity and
exhibit telomere shortening in culture. Also, telomere shortening was
associatedwith expression of a senescence phenotype inMSC cultures
[34,36]. We have tested the possibility of “rejuvenation” of MSC by
forced expression of hTERT [42] and found that these telomerizedMSC
exhibit enhanced bone-forming activity both in vitro and in vivo
besides promoting extended proliferation and differentiation ability of
MSC [42,61]. We have also reported recently [62] that telomerase
activity can be restored transiently to MSC by treatment with TSA
(trichostatin A) that changes the epigenetic status of hTERT protomer.
Unfortunately, long-term telomerization of the MSC leads to genetic
instability and tumor formation [62]. Thus, alternative, short-term or
conditional activation of telomerase may be a better approach for
clinical intervention that remains to be examined.
5.2. Identiﬁcation of Notch signaling in MSC aging
The identiﬁcation of new molecular players involved in MSC
aging came from the studies on progeroid syndromes. Progeroid
syndromes (or accelerated aging syndromes) are caused by a single
gene defects which results in accelerating aging phenotypes. The
advantage is that aging features seen in such syndromes may result
from the acceleration of mechanisms postulated to play causal role
in aging and thus can give information on the contribution of a given
mechanism in normal aging. In progeroid syndromes where stem
cells have been studied a clear association among accelerated
telomere shortening, decrease number of stem cells, organ failure
and lifespan has been shown [63,64,66,67]. Werner syndrome (WS),
dyskeratosis congenital (DC) and Hutchinson-Gilford Progeria
syndrome (HGPS), are good example of this in the case of MSC
[65,66]. In HGPS, a rare, fatal genetic disorder that is characterized
by segmental accelerated aging with osteoporosis and accelerated
telomere shortening, a link between BMSC and osteoporosis has
been made. The major causal mutation associated with HGPS
triggers abnormal messenger RNA splicing of the laminin A gene.
Knock down of laminin A in BMSC has been shown to impair
osteoblastogenesis and accelerates osteoclastogenesis [67]. Gene
expression proﬁling of MSC overexpressing the abnormal form of
laminin A showed alterations in the activation of the Notch signaling
pathway [68]. Moreover, the abnormal form of laminin A has been
seen to increase in cells with physiological aging [69], suggesting
that, at least in certain circumstances, with age MSC may be affected
in a similar way to MSC from patients affected by HGPS. Indeed
Notch signaling has been shown to be important for the main-
tenance of the MSC pool in physiological conditions [70]. The
disruption of Notch signalling in the limb skeletogenic mesenchyme
markedly increased trabecular bone mass in adolescent mice whilst
in aged mice caused osteopenia [70].
369I. Bellantuono et al. / Biochimica et Biophysica Acta 1792 (2009) 364–370The identiﬁcation of Notch signalling as a pathway involved in self-
renewal of MSC opens up opportunities for drug discovery and
strategies to identify compounds which can be used to manipulate
stem cells for therapeutic or biotechnology purposes. Whilst con-
siderably more information is needed, progress is well underway with
proof-of-concept approaches. The ability of intervening and increasing
even modestly the stem cell pool may have great therapeutic impact.
Small molecule manipulation of both ES cells and adult tissue stem/
progenitor cells has shown that such an approach is feasible [71–73]. A
better understanding of themolecular basis ofMSC agingmay uncover
novel molecule capable of extending tissue survival and repair.
6. Concluding remarks
The inadequate and very variable technology available at present
for studying MSC and the diversity of mechanisms leading to aging
pose a major challenge to studying the contribution of MSC to the
aging phenotype and have led to the very variable results obtained in
different laboratories. Studying larger samples of the healthy aging
population is needed for an accurate analysis. Also, identiﬁcation of
better markers for the authenticMSC and amore controlled procedure
for bone marrow harvest and culture are important pre-requisites for
obtaining accurate data. Irrespective of these difﬁculties, the idea of
“rejuvenation” of stem cells either through transplantation or
activation of endogenous stem cells is highly relevant and may
provide a novel strategy for abolishing some of the age-related
diseases. In this context, studying the molecular mechanism under-
lying several of the progeria (accelerated-senescence) syndromes can
enhance our understanding of the mechanisms of aging and MSC
aging and thus provide novel targets for intervention.
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